Identification of novel androgen receptor target genes in prostate cancer, Molecular Cancer, vol.6, issue.1, p.39, 2007. ,
DOI : 10.1186/1476-4598-6-39
ELEVATION OF DIPEPTIDYLPEPTIDASE IV ACTIVITIES IN THE PROSTATE PERIPHERAL ZONE AND PROSTATIC SECRETIONS OF MEN WITH PROSTATE CANCER: POSSIBLE PROSTATE CANCER DISEASE MARKER, The Journal of Urology, vol.174, issue.3, pp.1124-1128, 2005. ,
DOI : 10.1097/01.ju.0000168621.84017.5c
Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer, Molecular Immunology, vol.45, issue.3, pp.839-848, 2008. ,
DOI : 10.1016/j.molimm.2006.11.026
A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9, DNA and Cell Biology, vol.27, issue.4 ,
DOI : 10.1089/dna.2007.0667
Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters, The Prostate, vol.59, issue.3, pp.243-253, 1992. ,
DOI : 10.1002/pros.2990200309
Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis, British Journal of Cancer, vol.70, issue.6, pp.1252-1257, 1994. ,
DOI : 10.1038/bjc.1994.482
Apoptosis incidence and protein expression of p53, TGF-?? receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate1 1Accepted for publication 0, 2003., Human Pathology, vol.35, issue.3, pp.290-297, 2004. ,
DOI : 10.1016/j.humpath.2003.11.001
Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP, Clinical Cancer Research, vol.10, issue.1, pp.314-323, 2004. ,
DOI : 10.1158/1078-0432.CCR-0846-3
Development of Quantitative Detection Assays for CYR61 as a New Marker for Benign Prostatic Hyperplasia, Journal of Biomolecular Screening, vol.8, issue.6, pp.701-711, 2003. ,
DOI : 10.1177/1087057103259159
Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate, Urology, vol.67, issue.1, pp.204-208, 2006. ,
DOI : 10.1016/j.urology.2005.07.045
EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA, The Journal of Urology, vol.174, issue.5, pp.2046-2050, 2005. ,
DOI : 10.1097/01.ju.0000176459.79180.d1
Activation of Caspases-3, -6, and -9 during Finasteride Treatment of Benign Prostatic Hyperplasia, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.1, pp.17-25, 2005. ,
DOI : 10.1210/jc.2004-0712
Distribution of 15 Human Kallikreins in Tissues and Biological Fluids, Clinical Chemistry, vol.53, issue.8, pp.1423-1432, 2007. ,
DOI : 10.1373/clinchem.2007.088104
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia, International Journal of Oncology, vol.29, pp.305-314, 2006. ,
DOI : 10.3892/ijo.29.2.305
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia, Rev Urol, vol.5, pp.12-21, 2003. ,
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis ,
MOLECULAR PROFILING OF BENIGN PROSTATIC HYPERPLASIA USING A LARGE SCALE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION APPROACH, The Journal of Urology, vol.172, issue.4 ,
DOI : 10.1097/01.ju.0000137819.92305.46
Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis, The Prostate, vol.1, issue.3, pp.189-200, 2002. ,
DOI : 10.1002/pros.10087
Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?, European Urology, vol.51, issue.5, pp.1202-1216, 2007. ,
DOI : 10.1016/j.eururo.2006.12.011
Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays, Proceedings of the National Academy of Sciences, vol.99, issue.11 ,
DOI : 10.1073/pnas.112191399